GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (NAS:APDN) » Definitions » Cyclically Adjusted Price-to-FCF

APDN (Applied DNA Sciences) Cyclically Adjusted Price-to-FCF : (As of Jun. 02, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Applied DNA Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Applied DNA Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Applied DNA Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied DNA Sciences Cyclically Adjusted Price-to-FCF Chart

Applied DNA Sciences Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Applied DNA Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Applied DNA Sciences's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Applied DNA Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied DNA Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Applied DNA Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Applied DNA Sciences's Cyclically Adjusted Price-to-FCF falls into.


;
;

Applied DNA Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Applied DNA Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Applied DNA Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-28.559/134.9266*134.9266
=-28.559

Current CPI (Mar. 2025) = 134.9266.

Applied DNA Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -1,255.000 100.684 -1,681.827
201509 -1,739.000 100.392 -2,337.223
201512 -2,787.000 99.792 -3,768.227
201603 -2,603.000 100.470 -3,495.696
201606 -2,699.000 101.688 -3,581.214
201609 -2,593.000 101.861 -3,434.726
201612 -2,112.000 101.863 -2,797.540
201703 -2,681.000 102.862 -3,516.726
201706 -1,884.000 103.349 -2,459.641
201709 -948.000 104.136 -1,228.306
201712 -2,621.000 104.011 -3,400.047
201803 -862.000 105.290 -1,104.637
201806 -1,195.000 106.317 -1,516.574
201809 -2,505.000 106.507 -3,173.426
201812 -1,566.000 105.998 -1,993.389
201903 -2,300.000 107.251 -2,893.517
201906 -1,288.000 108.070 -1,608.090
201909 -1,776.000 108.329 -2,212.046
201912 -910.333 108.420 -1,132.891
202003 -605.000 108.902 -749.582
202006 -601.800 108.767 -746.537
202009 -596.600 109.815 -733.026
202012 -747.667 109.897 -917.954
202103 -582.857 111.754 -703.712
202106 -250.429 114.631 -294.767
202109 -802.571 115.734 -935.662
202112 -543.857 117.630 -623.830
202203 -41.000 121.301 -45.605
202206 -203.444 125.017 -219.571
202209 -269.385 125.227 -290.252
202212 -183.308 125.222 -197.515
202303 16.462 127.348 17.442
202306 -105.308 128.729 -110.378
202309 -191.429 129.860 -198.899
202312 -268.429 129.419 -279.851
202403 -3,210.000 131.776 -3,286.742
202406 -699.000 132.554 -711.513
202409 -15.772 133.029 -15.997
202412 -81.976 133.157 -83.065
202503 -28.559 134.927 -28.559

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Applied DNA Sciences  (NAS:APDN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Applied DNA Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied DNA Sciences Business Description

Traded in Other Exchanges
N/A
Address
50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Executives
Clay Shorrock officer: Chief Legal Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Scott L Anchin director 16990 GOLDENTOP ROAD, SUITE A, SAN DIEGO CA 92127
William W Montgomery 10 percent owner 34211 SEAVEY LOOP RD., EUGENE OR 97405
Judith Murrah officer: Chief Information Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Beth Jantzen officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov A Shamash director
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
John Iii Bitzer director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Joseph D. Ceccoli director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Elizabeth M. Ferguson director 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Charles S. Ryan director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
James A Hayward director, officer: Chief Executive Officer C/O 25 HEALTH SCIENCES DRIVE, SUITE 113, NEW YORK NY 11790
Karol Gray officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Ming-hwa Benjamin Liang officer: Strategic Tech. Dev. Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov Shamash director 100 ENGINEERING, STATE UNIVERSITY OF NY, STONE BROOK NY 117942200